Compare Essex Property Trust, Inc. (ESS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Sana Biotechnology Inc — how do they compare? Essex Property Trust, Inc. trades at $271.57 (market cap $17.26B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Essex Property Trust, Inc. is far larger — about 20.6× Sana Biotechnology Inc's market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Sana Biotechnology Inc for 23 Days on average.
| ESS | SANA | |
|---|---|---|
Market Cap | $17.26B | $836.71M |
Volume | 454,464 | 4,507,444 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $5.92 |
52-Week Low | $239.61 | $2.68 |
Typical Hold Time | 111 Days | 23 Days |
Enterprise Value | $23.86B | $749.96M |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $273.21, up 1.93% today, but technical indicators signal a bearish trend with resistance near $273. The company reported mixed quarterly earnings, beating in Q1 but missing in Q2 and Q4 2025, while maintaining strong profitability with a net margin of 21.48%. Recent news highlights strong Q2 2026 results and the resolution of litigation, improving the risk profile.
The outlook is cautiously optimistic with a consensus price target of $303.41, implying upside, but risks include earnings volatility and high debt levels. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid ongoing operational execution challenges in the real estate sector.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
